Your shopping cart is currently empty

NF-κΒ Activator 2 is a potent, orally active compound that efficiently activates NF-κB with an EC50 value of 1.58 μM. By enhancing NF-κB expression and activation, it induces SOD 2 synthesis, rendering it useful for amyotrophic lateral sclerosis (ALS) research [1].

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $95 | In Stock | In Stock | |
| 2 mg | $138 | In Stock | In Stock | |
| 5 mg | $238 | In Stock | In Stock | |
| 10 mg | $353 | In Stock | In Stock | |
| 25 mg | $567 | In Stock | In Stock | |
| 50 mg | $768 | In Stock | In Stock | |
| 100 mg | $987 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $262 | In Stock | In Stock |
| Description | NF-κΒ Activator 2 is a potent, orally active compound that efficiently activates NF-κB with an EC50 value of 1.58 μM. By enhancing NF-κB expression and activation, it induces SOD 2 synthesis, rendering it useful for amyotrophic lateral sclerosis (ALS) research [1]. |
| Targets&IC50 | NF-κB:1.58 μM (EC50) |
| In vitro | NF-κB activator 2 (Compound 61) (1 μM, 6 hr) induces SOD 2 mRNA expression in SH-SY5Y neuroblastoma cells [1]. SOD2 is a highly inducible SOD that performs in concurrence with SOD1 to detoxify ROS. Induction of SOD2 can be obtained through the activation of NF-ҡBs. |
| In vivo | NF-κΒ activator 2, when administered intravenously (i.v.) at a dose of 1 mg/kg, demonstrates an appropriate half-life of 0.96 hours in mice [1]. Similarly, at an oral (p.o.) dosage of 5 mg/kg, it shows a comparable half-life of 2.86 hours, an oral bioavailability of 15.6%, and a maximum concentration (C max) of 92 ng/mL [1]. |
| Molecular Weight | 298.27 |
| Formula | C16H11FN2O3 |
| Cas No. | 2375281-44-8 |
| Smiles | OC(=O)c1cccc(c1)-c1cnc(Nc2ccccc2F)o1 |
| Relative Density. | 1.396 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 250 mg/mL (838.17 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (16.76 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.